NASDAQ: SGMT - Sagimet Biosciences Inc. Series A Common Stock

Yield per half year: +68.6%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Sagimet Biosciences Inc. Series A Common Stock

Extended chart Simple chart
Financial Markets by TradingView

About Sagimet Biosciences Inc. Series A Common Stock

Sagimet Biosciences Inc., биофармацевтическая компания клинической стадии, разрабатывает терапевтические средства, называемые ингибиторами синтазы жирных кислот (FASN), для лечения важных заболеваний, таких как неалкогольный стеатогепатит, акне и различные виды рака. Он предлагает Денифанстат, ингибитор синтазы жирных кислот для лечения неалкогольного стеатогепатита. Компания также разрабатывает TVB-3567, ингибитор FASN. Sagimet Biosciences Inc., ранее известная как 3-V Biosciences, Inc., сменила название на Sagimet Biosciences Inc. в августе 2019 года.

more details
Компания была зарегистрирована в 2006 году и базируется в Сан-Матео, Калифорния.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2023-07-14
ISIN US7867001049
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://sagimet.com
Цена ао 5.23
Change price per day: -2.76% (5.08)
Change price per week: -0.202% (4.95)
Change price per month: -10.83% (5.54)
Change price per 3 month: +75.18% (2.82)
Change price per half year: +68.6% (2.93)
Change price per year: -8.86% (5.42)
Change price per 3 year: 0% (4.94)
Change price per 5 year: 0% (4.94)
Change price per 10 year: 0% (4.94)
Change price per year to date: -14.97% (5.81)
All parameters

Underestimation

Title Value Grade
P/S 69.43 1
P/BV 1.52 8
P/E 0 0
EV/EBITDA -2.08 0
Total: 4.25

Efficiency

Title Value Grade
ROA, % -28.82 0
ROE, % -30.61 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0021 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 116.48 10
Yield EPS, % 314.39 10
Total: 7.8
More

Institutions Volume Share, %
NEA Management Company, LLC 3850275 12.67
FMR, LLC 1922056 6.32
Baker Brothers Advisors, LLC 1456518 4.79
HHLR Advisors, LTD 1449543 4.77
Artal Group S.A. 924771 3.04
Rock Springs Capital Management, LP 738355 2.43
PFM Health Sciences, LP 676453 2.23
Alyeska Investment Group, L.P. 486560 1.6
Altium Capital Management, LP 483181 1.59
Blackrock Inc. 387401 1.27

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.02142 17.09 1.54048



Head Job title Payment Year of birth
Dr. George W. Kemble Ph.D. Executive Chairman of the Board 484k 1962 (63 years)
Mr. David A. Happel CEO, President & Director 506.46k 1962 (63 years)
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. Chief Medical Officer 446.49k 1963 (62 years)
Mr. Urs Greber Ph.D. Co-Founder N/A
Dr. Lucas Pelkmans Ph.D. Co-Founder N/A
Ms. Elizabeth Rozek Esq., J.D. General Counsel & Chief Compliance Officer N/A 1972 (53 years)
Mr. Thierry Chauche CFO & Principal Accounting Officer 1976 (49 years)
Dr. Marie O'Farrell Ph.D. Senior Vice President of Research & Development

Address: United States, San Mateo. CA, 155 Bovet Road - open in Google maps, open in Yandex maps
Website: https://sagimet.com